Top 20 life sciences deals of 2025 show a bigger-bet market

PharmaShots’ new Top 20 Life Sciences Deals of 2025 roundup offers a useful snapshot of where money and strategic attention went last year: toward bigger, more selective transactions, with a strong mix of biopharma M&A, licensing, and platform partnerships. The ranking, produced with DealForma data, includes deals such as Shionogi’s approximately $2.5 billion acquisition of Mitsubishi Tanabe Pharma’s RADICAVA business, Pfizer’s oncology licensing pact with 3SBio, and Bristol Myers Squibb’s multibillion-dollar collaboration with BioNTech around BNT327. (pharmashots.com)

The broader backdrop helps explain why this list matters. DealForma’s 2025 review found that global healthcare and life sciences R&D partnerships fell in number to 685 deals, but still produced $273.6 billion in total value, signaling a shift toward fewer, larger bets. M&A also rebounded sharply, reaching 585 transactions worth $269.3 billion, versus $140.8 billion in 2024. In other words, 2025 wasn’t simply busier, it was more concentrated around larger, more strategic assets. That concentration was echoed in public-market financing: PharmaShots’ Top 20 Healthcare IPOs of 2025 said the year’s listings reflected sustained investor confidence across biotech, medtech, digital health, and AI-enabled healthcare, with capital flowing disproportionately to scaled platforms, advanced diagnostics, precision medicine, and revenue-generating businesses. Medline Industries led by a wide margin with a $7.2 billion IPO, followed by Caris Life Sciences at $494 million and Lumexa Imaging at $462.5 million. (dealforma.com, pharmashots.com)

PharmaShots’ list reflects that concentration. At the lower end of the top 20, Shionogi’s RADICAVA transaction stood out as a rare disease commercial play, with PharmaShots noting the business was expected to generate about $700 million in annual global sales. Elsewhere on the list, Thermo Fisher’s purchase of Solventum’s Purification & Filtration business showed continued appetite for bioprocessing and manufacturing infrastructure, while licensing deals from companies including ABL Bio, 3SBio, and Jiangsu Hengrui highlighted demand for platform science and pipeline assets rather than just full-company takeouts. The IPO data points in a similar direction: investors favored technology-integrated healthcare stories, including AI-driven drug discovery, oncology, metabolic disease, digital care, and advanced medtech platforms such as Saluda Medical’s neuromodulation business and Shenzhen Edge Medical’s surgical robotics offering. (pharmashots.com, pharmashots.com)

Two themes were especially visible. First, oncology and immunology remained central to dealmaking. Pfizer’s May 2025 agreement with 3SBio gave it ex-China rights to SSGJ-707, a PD-1/VEGF bispecific antibody, for an upfront payment of about $1.25 billion plus up to $4.8 billion in milestones and a $100 million equity investment, for a package valued at more than $6 billion. Second, big pharma continued to put real money behind next-generation biologics and bispecifics: Bristol Myers Squibb said it would pay BioNTech $1.5 billion upfront, plus $2 billion in non-contingent anniversary payments through 2028, with up to $7.6 billion more in milestones tied to BNT327. Beyond oncology, buyers were also willing to spend heavily in other specialty areas. Eli Lilly’s planned acquisition of Centessa Pharmaceuticals, valued at about $7.8 billion, would add cleminorexton and ORX142 and expand Lilly’s neuroscience and sleep-medicine portfolio through a structure combining roughly $6.3 billion upfront with a contingent value right worth about $1.5 billion if regulatory milestones are met. (pharmashots.com, pharmashots.com)

Industry commentary suggests this wasn’t random. Nature, citing DealForma, reported a substantial increase in 2025 dealmaking between large global pharma companies and Chinese biopharma companies, with about 38% of big pharma deals and 28% of upfront payments tied to Chinese counterparties. DealForma founder and CEO Chris Dokomajilar told Nature that this was a notable shift in the market, and the 3SBio-Pfizer agreement was one of the examples cited. That aligns with the PharmaShots ranking, where several high-value deals involved China-originated science, ex-China rights structures, or option-based licensing models. The same cross-border and platform orientation was visible in financing markets too, including Chinese medtech participation in the IPO rankings such as Shenzhen Edge Medical. (nature.com, pharmashots.com)

Another signal from 2025 is that specialist capital remains available for large healthcare bets. Blackstone closed Blackstone Life Sciences VI at its $6.3 billion hard cap, making it roughly 40% larger than its predecessor and, according to PharmaShots, the largest life sciences vehicle of its kind. Blackstone said the BXLS platform had about $15 billion in assets under management as of the fourth quarter of 2025 and had committed around $2 billion over the previous 12 months through partnerships with companies including Merck, Teva, Alnylam, and Novartis. That matters because it suggests the market’s selectivity is not the same as retrenchment: there is still substantial capital for drug, medtech, and royalty transactions when the asset profile fits. (pharmashots.com)

Private equity also remained active in established specialty pharma. PharmaShots reported that CVC Capital Partners proposed a voluntary tender offer valuing Recordati at about €10.9 billion, or €52 per share, with the aim of acquiring all outstanding shares and delisting the company. Recordati had previously expanded into rare disease through its 2021 acquisition of EUSA Pharma, strengthening its rare cancer portfolio. Even though the proposal was non-binding and subject to due diligence and financing, it fit the broader 2025 pattern: buyers were willing to pursue scaled, commercially established assets in attractive specialty categories. (pharmashots.com)

Why it matters: For veterinary professionals, the direct read-through is less about any one human drug deal and more about the market logic underneath them. When large strategics and specialist investors reward de-risked products, specialty commercial infrastructure, bispecific platforms, AI-enabled discovery, manufacturing capabilities, and revenue-generating diagnostics, those priorities can shape the broader health innovation ecosystem, including diagnostics, translational research tools, and financing conditions that eventually affect animal health. Veterinary companies competing for capital or partnerships may face a market that increasingly favors clear clinical differentiation, platform leverage, commercial readiness, and scalable technology over earlier, less-defined stories. That’s an inference from the 2025 deal and IPO pattern, but it’s a reasonable one given the concentration of value in biopharma, diagnostics, medtech, and platform businesses and the rise in average transaction size. (dealforma.com, pharmashots.com, pharmashots.com)

There’s also a practical workforce and supply-chain angle. Large human-health deals can redirect manufacturing capacity, BD attention, and investor appetite across adjacent sectors. Thermo Fisher’s bioprocessing expansion, for example, underscores how infrastructure assets remain strategically important, while rare disease, neuroscience, and oncology transactions show that companies are still willing to spend for products with established revenue or late-stage momentum. For veterinary teams watching consolidation, partnering, or diagnostic innovation, 2025’s life sciences deal table is a reminder that capital is still available, but it’s being deployed with more selectivity and at larger scale. (pharmashots.com, pharmashots.com)

What to watch: In 2026, the key question is whether this large-deal momentum broadens into more veterinary-adjacent diagnostics, data, medtech, and specialty therapeutics, or stays concentrated in human biopharma, rare disease, oncology, and neuroscience platforms. Watch, too, whether private equity and large specialist funds keep backing established healthcare businesses and late-stage assets, as suggested by Blackstone’s record fundraise and CVC’s move on Recordati. Deal volume alone may matter less than where buyers and investors see de-risked growth, and that’s likely to remain the organizing principle for the next wave of transactions. (dealforma.com, pharmashots.com, pharmashots.com)